Other Events ·
Sionna Therapeutics announced that its PreciSION CF Phase 2a trial of SION-719 failed to meet the primary endpoint…
SIONSionna Therapeutics, Inc.
Sionna Therapeutics announced that its PreciSION CF Phase 2a trial of SION-719 failed to meet the primary endpoint, showing no significant sweat chloride reduction when added to standard of care. Consequently, the company will not advance SION-719 as an add-on therapy. However, a Phase 1 trial of SION-451 dual combinations met safety and pharmacokinetic objectives, identifying SION-451 plus SION-2222 as the preferred combination for further evaluation. With approximately $268.3 million in cash at the end of Q2, Sionna plans to preserve capital while determining next steps for its pipeline. The company operates in the biopharmaceutical industry, developing novel medicines for cystic fibrosis.